The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas is a research paper published in Acta Neuropathologica Communications (2020). On theSindex it has a DataRank of 0. It has been cited 50 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institute of Neurological Disorders and Stroke
Grant: R01NS102669
National Cancer Institute
Grant: P50CA221747
National Institutes of Health
Grant: 5R01NS102669-02
Tissue Factor as a Key Determinant of IDH1 Mutant versus IDH1 Wild-type Glioma Thrombosis and Malignancy
National Institutes of Health
Grant: 5P50CA221747-02
SPORE for Translational Approaches to Brain Cancer
FWCI
3.61
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas
Additional file 1 of The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas
Additional file 2 of IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation
Additional file 2 of IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation
The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas
The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas